Does Adjuvant Chemotherapy Dose Modification Have an Impact On the Outcome of Patients diagnosed with Advanced Stage Ovarian Cancer? An NRG Oncology/Gynecologic Oncology Group Study

PURPOSE: To determine the relationship between chemotherapy dose modification (dose adjustment or treatment delay), overall survival (OS) and progression-free survival (PFS) for women with advancedstage epithelial ovarian carcinoma (EOC) and primary peritoneal carcinoma (PPC) who receive carboplatin...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Gynecol Oncol
Hlavní autoři: Olawaiye, Alexander B., Java, James J., Krivak, Thomas C., Friedlander, Michael, Mutch, David G., Glaser, Gretchen, Geller, Melissa, O’Malley, David M., Wenham, Robert M., Lee, Roger B., Bodurka, Diane C., Herzog, Thomas J., Bookman, Michael A.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2018
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6151871/
https://ncbi.nlm.nih.gov/pubmed/30135020
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ygyno.2018.07.021
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky